- Report
- February 2026
- 250 Pages
Global
From €4160EUR$4,490USD£3,483GBP
- Report
- January 2026
- 180 Pages
Global
From €4169EUR$4,500USD£3,491GBP
- Report
- September 2026
- 191 Pages
Global
From €3284EUR$3,545USD£2,750GBP
€3649EUR$3,939USD£3,056GBP
- Report
- May 2026
- 100 Pages
Global
From €2501EUR$2,699USD£2,094GBP
- Report
- August 2025
Global
From €4540EUR$4,900USD£3,801GBP
- Clinical Trials
- April 2025
- 40 Pages
Global
From €1158EUR$1,250USD£970GBP
- Report
- June 2024
- 200 Pages
Global
From €7365EUR$7,950USD£6,167GBP
- Report
- May 2024
- 134 Pages
Global
From €3705EUR$3,999USD£3,102GBP
- Report
- July 2022
- 71 Pages
Global
From €1853EUR$2,000USD£1,552GBP
The Hepatitis D Drug market is a subset of the Infectious Diseases Drugs market, focusing on treatments for the Hepatitis D virus. This virus is a serious infection of the liver, and is often contracted in conjunction with the Hepatitis B virus. Treatment for Hepatitis D is typically a combination of antiviral medications and supportive care. These medications are designed to reduce the amount of virus in the body, and to reduce the risk of complications.
The Hepatitis D Drug market is highly competitive, with a number of companies offering treatments for the virus. Some of the major players in the market include Gilead Sciences, AbbVie, Merck, and Bristol-Myers Squibb. These companies offer a range of treatments, including antiviral medications, vaccines, and supportive care. Show Less Read more
